MedTrace Logo

A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer

NCT05705635 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-01-31

No results posted yet for this study

Summary

This trial is a multicenter, randomized, controlled clinical study to evaluate the efficacy and safety of Docetaxel for Injection (Albumin-bound) and Taxotere in locally advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.

Conditions

  • Gastric Adenocarcinoma
  • Adenocarcinoma of Gastroesophageal Junction

Interventions

DRUG

Docetaxel for injection (Albumin-bound)

Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks.

DRUG

Taxotere

Taxotere, by intravenous infusion, every 3 weeks.

Sponsors & Collaborators

  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Ruihua Xu · Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-13
Primary Completion
2023-05-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05705635 on ClinicalTrials.gov